Otsuka v. Lupin — Federal Circuit Affirms Noninfringement and Obviousness of Kidney Drug Patents

Background

Otsuka Pharmaceutical owns two patents — U.S. Patent Nos. 8,501,730 and 8,273,735 — covering highly pure tolvaptan and improved methods for synthesizing it. Tolvaptan is the active ingredient in JYNARQUE®, used to treat Autosomal Dominant Polycystic Kidney Disease (ADPKD). The patents’ key innovation involves reducing the amount of a hydrogenating agent (sodium borohydride) used during synthesis, which cuts down on a troublesome impurity called the “dechlorinated impurity.”

Lupin Ltd. filed an Abbreviated New Drug Application (ANDA) seeking FDA approval for generic versions of JYNARQUE®. Lupin’s manufacturing process uses at least 1.2 molar equivalents of sodium borohydride — more than the 0.25 to 1 molar equivalent range claimed in Otsuka’s patents. Otsuka sued for infringement in the District of Delaware. After a bench trial, the district court ruled that Lupin did not infringe and that certain claims of the ‘735 patent were invalid for obviousness.

The Court’s Holding

The Federal Circuit affirmed on all grounds. On infringement, the key question was how to define the “amount” of hydrogenating agent while the reduction reaction “is taking place.” The district court adopted a “practical completion” framework — measuring the amount present until the reaction is essentially done — and found that Otsuka failed to prove that Lupin’s reaction reaches practical completion before more than 1 molar equivalent of sodium borohydride has been added. The Federal Circuit agreed, finding no clear error in the district court’s assessment of the evidence, including its decision to discount flawed experimental data from Lupin’s development-stage experiments.

On expert qualification, the court held that Otsuka forfeited its challenge to Lupin’s expert, Dr. Dichtel, by failing to file a Daubert motion or object at trial when Dr. Dichtel testified as a skilled artisan — despite raising the issue elliptically in its opening statement.

On obviousness, the Federal Circuit found no clear error in the district court’s conclusion that the prior art reference Kondo — which taught a process for synthesizing tolvaptan at lab scale — provided a viable starting point. The court credited testimony that a skilled chemist would have been motivated to reduce the amount of sodium borohydride for cost, safety, and processing reasons, and found that the strong prima facie case of obviousness was not overcome by Otsuka’s secondary-consideration evidence of unexpectedly high yield.

Key Takeaways

• In ANDA litigation, patentees must present reliable experimental evidence to prove infringement — flawed or anomalous lab data will not suffice, even when buttressed by expert testimony.
• Challenges to an opposing expert’s qualifications must be raised before or during trial (via Daubert motion or timely objection). Mentioning the issue in an opening statement is not enough to preserve the argument.
• Strong prima facie obviousness evidence can withstand secondary considerations like unexpected results, especially when the patentee’s comparative data is measured against conditions different from the closest prior art.

Why It Matters

This ruling clears a path for Lupin’s generic version of JYNARQUE®, a kidney disease treatment with significant annual costs for patients. More broadly, the case underscores the Federal Circuit’s deference to well-supported district court factual findings after bench trials in Hatch-Waxman cases. It also serves as a cautionary tale about trial preservation — pharmaceutical patent holders must formally challenge opposing experts’ qualifications before or during trial, not wait for post-trial briefing. The decision is nonprecedential but consistent with the court’s approach to ANDA infringement and obviousness analysis.